Rankings
▼
Calendar
MYGN Q2 2024 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena
MYGN
Myriad Genetics, Inc.
$487M
Q2 2024 Earnings
Healthcare
Medical - Diagnostics & Research
Income Statement
Revenue
$212M
+15.3% YoY
Gross Profit
$147M
69.6% margin
Operating Income
-$37M
-17.3% margin
Net Income
-$37M
-17.4% margin
EPS (Diluted)
$-0.41
QoQ Revenue Growth
+4.6%
Cash Flow
Operating Cash Flow
$3M
Free Cash Flow
-$6M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$345M
Stockholders' Equity
$741M
Cash & Equivalents
$92M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$212M
$184M
+15.3%
Gross Profit
$147M
$126M
+17.0%
Operating Income
-$37M
-$114M
+67.9%
Net Income
-$37M
-$116M
+68.4%
Geographic Segments
UNITED STATES
$195M
92%
Non-US
$17M
8%
← FY 2024
All Quarters
Q3 2024 →